Industry Revenues:

• Life Sciences: 100% (2026)

TOP 3 Markets:

• USA: 45%
• Europe: 30%
• Asia-Pacific: 15%

10x Genomics, Inc. generates all its revenues from the Life Sciences industry, particularly through the sale of instruments and reagents for single-cell and spatial transcriptomics.

The company's largest market is the USA, followed by Europe and the Asia-Pacific region. These markets are crucial for the company's growth as they exhibit high demand for advanced genomic solutions.

Production Sites: Pleasanton, California, USA

10x Genomics, Inc. primarily produces its products in Pleasanton, California. The company has its main production facilities there and develops its technologies and products on site. This strategic location allows the company to operate near key technology centers and research institutions, supporting innovation and production efficiency.

Research and Development Investments: 30% of revenue (2025)
Market Expansion: Increase international presence by 20% (2025)

10x Genomics, Inc. pursues a growth strategy that heavily relies on innovation and expansion. The company invests significantly in research and development to expand its product range in the field of genomics technologies. These investments account for approximately 30% of revenue, highlighting the importance of innovation for the company.

In addition, 10x Genomics focuses on tapping into new international markets. The 20% increase in international presence indicates that the company is striving to expand its global reach and reach new customer segments. This strategy is supported by partnerships and collaborations with leading research institutions and universities.

Through these measures, the company expects to further strengthen its market leadership in the field of single-cell and spatial genomics and achieve sustainable long-term growth.

Main materials: Microchips, reagents, plastic components

Countries of origin: USA, China, Germany

10x Genomics, Inc. is a company specializing in the development and production of genomics technologies. The company requires various raw materials and components for the manufacturing of its products. These include microchips, which are typically imported from the USA and China, as these countries are leading in semiconductor production.

Reagents, essential for biotechnological applications, are often sourced from specialized chemical companies in Germany and other European countries. Plastic components needed for the production of laboratory equipment and consumables come from both the USA and international markets, depending on specific requirements and availability.

The exact origin may vary depending on supply chain strategies and geopolitical developments, but the mentioned countries are typical sources for the required materials.

Market Share: 30% (estimated for 2026)
Research & Development Expenses: $150 million (2025)
Patent Portfolio: Over 1,000 patents (2025)

10x Genomics, Inc. has gained a significant competitive advantage in the genomics industry, particularly through its innovative technology platform that enables researchers to analyze biological systems at the single-cell level. The company holds an estimated market share of 30%, highlighting its strong position in a rapidly growing market.

An essential aspect of 10x Genomics' competitive advantage is its extensive patent portfolio with over 1,000 patents, securing its technological leadership and making market entry difficult for competitors. Additionally, the company continuously invests in research and development, with expenses of $150 million in 2025, to further improve its products and develop new technologies.

In addition, 10x Genomics benefits from strong partnerships with leading research institutions and a broad customer base that promotes the application of its technologies in various areas of biomedical research. These factors contribute to the company maintaining and expanding its market leadership.

Institutional Investor Ownership: 75% (estimated, 2026)
Insider Buys/Sells: No significant insider transactions in the last year (2026)

The institutional investor ownership in 10x Genomics, Inc. is estimated to be around 75%. This indicates a high level of confidence from institutional investors in the company, suggesting a stable market position and positive growth prospects.

No significant insider transactions were reported in 2026. This could suggest that the management has confidence in the current company strategy and future business outlook. However, it is always advisable to regularly monitor insider activities to detect potential changes in corporate leadership or strategy early on.

Market share of 10x Genomics: Estimated 25% (2026)

Main competitors and their market shares:

1. Illumina, Inc.: 30%
2. Thermo Fisher Scientific Inc.: 20%
3. Becton, Dickinson and Company: 10%
4. Agilent Technologies, Inc.: 8%
5. Bio-Rad Laboratories, Inc.: 7%

10x Genomics has gained a significant market share in the single-cell genomics field. The company's moat is based on its innovative technology platform, which enables the analysis of complex biological systems at the single-cell level. This technology is difficult to replicate and provides a clear advantage over many competitors.

However, Illumina remains a strong competitor with a larger market share, especially due to its established position in the field of sequencing technologies. Thermo Fisher Scientific also offers a wide range of products and services that allow it to maintain a significant market share.

The moat of 10x Genomics is strong, but the competition is not standing still. Companies like Illumina and Thermo Fisher Scientific also have deeply rooted technologies and extensive resources to defend and expand their market positions.

Revenue Growth: 18% (2025) Research and Development Ratio: 25% of revenue (2025) Market Share in Single-Cell Genomics: 40% (2025)

10x Genomics, Inc. recorded a revenue growth of 18% in 2025, driven by the increasing demand for single-cell genomics technologies. The company is heavily investing in research and development, with a ratio of 25% of revenue, indicating strong innovation capabilities.

10x Genomics' market share in the field of single-cell genomics is approximately 40%, making the company a leading player in this sector. This position could secure competitive advantages in the long term.

In summary, 10x Genomics represents an attractive investment opportunity due to its strong revenue growth, high investments in research and development, and leading market position, especially for investors interested in the long-term development of the genomics industry.

Dividend: None (as of 2026)

10x Genomics, Inc. currently does not pay any dividends to its shareholders. The company has historically focused on reinvesting its profits into research and development, as well as into the growth and expansion of its business operations.

As 10x Genomics operates in a highly research and development-intensive industry, it is common for companies in this sector not to pay dividends, but rather to invest their resources in advancing their technologies and products. This can potentially lead to a higher company value in the long term, which may be attractive to investors who prioritize capital growth over current income.